米非司酮治疗子宫内膜异位症患者的随机前瞻性研究  

Randomized Prospective Study of Mifepristone in Patients with Endometriosis

作　　者：李媛 LI Yuan(Fengxin County People's Hospital,Fengxin Jiangxi 330700,China)

机构地区：[1]奉新县人民医院,江西奉新330700

出　　处：《药品评价》2024年第8期1038-1040,共3页Drug Evaluation

摘　　要：目的探究子宫内膜异位症使用米非司酮治疗的临床效果。方法将奉新县人民医院2020年1月到2022年10月期间医治的84例患有子宫内膜异位症患者作为研究对象,随机将其分成两组,每组42例,对照组给予孕三烯酮治疗,观察组给予米非司酮治疗,比较两组临床效果,性激素水平,肿瘤标志物[糖类抗原(CA125、CA199)],炎症细胞因子[白介素-4(IL-4)、白介素-8(IL-8)、血管内皮生长因子A(VEGFA)]。结果观察组总有效率明显高于对照组;治疗后两组肿瘤标志物CA125,CA199较治疗前均降低,且观察组CA125,CA199水平更低;治疗后两组炎症细胞因子IL-4、IL-8、VEGFA均比治疗前低,且观察组IL-4、IL-8、VEGFA水平减少更多,均差异有统计学意义(P<0.05)。结论对子宫内膜异位症患者使用米非司酮治疗的效果十分明显,可调节机体激素,降低肿瘤标志物表达水平,抑制新生血管生长,调节免疫水平。Objective To study the clinical efficacy of mifepristone in the treatment of endometriosis.Methods 84 cases of endometriosis patients admitted to Fengxin County People's Hospital from January 2020 to October 2022 were divided into control group and observation group according to random number table method,with 42 cases in each group.The control group was given gestrinone treatment,and the observation group was given mifepristone treatment.The clinical effects,sex hormone levels,tumor markers[carbohydrate antigen(CA125,CA199)],inflammatory cytokines[interleukin-4(IL-4),interleukin-8(IL-8)],and vascular endothelial growth A(VEGFA)of the two groups were compared.Results The total efficiency in the observation group was significantly higher than that in the control group.After treatment,tumor markers CA125 and CA199 in the 2 groups were lower than before treatment,and the observation group were lower.The inflammatory cytokines IL-4,IL-8 and VEGFA were lower in the 2 groups than before treatment,and the observation group were lower,all the differences were statistically significant(P<0.05).Conclusion Mifepristone has definite clinical effect in the treatment of endometriosis,can effectively inhibit the growth of new blood vessels and the expression of tumor markers.Mifepristone can also regulate the hormone and immune levels.

关 键 词：子宫内膜异位症 米非司酮 糖类抗原 性激素 细胞因子 

分 类 号：R711.71[医药卫生—妇产科学]